Welcome to the 3rd Next-Generation Conjugates Summit
Driving Innovation in Conjugate Design, Validating Clinical Proof-of Concept & Streamlining CMC of Conjugates with Novel Payloads & Formats
Traditional ADCs have seen significant success in recent years, but still face many challenges, from limited payload capacities to significant toxicities.
Given these limitations, drug developers are venturing beyond the conventional boundaries of conjugate drug design, by exploring novel payloads and targeting formats, with companies including VincerX Pharma, Dyne Therapeutics, and Orum Therapeutics currently awaiting clinical validation.
Join 150+ of your peers to share learnings and collaborate on novel design concepts, key translational and clinical development challenges, and address challenging CMC roadblocks for the next generation of conjugated therapeutics, including antibody-oligonucleotide conjugates, fragment-drug conjugates, antibody-degrader conjugates, small molecule-drug conjugates, and bispecific-drug conjugates and more!
World-Class Speaker Faculty Includes:
Executive Director, R&D Chemistry
Senior Director - Research & Development
Senior Vice President, Innovation Chemistry and Alnylam Distinguished Scientist
Previously Attending Companies Include:
‘With the explosion of antibody conjugates with different payloads, this is a terrific opportunity for colleagues to come together and share challenges and learnings across different modalities’ - Amgen
‘This year’s format with separate discovery and development tracks is particularly exciting. While equally important, it should provide a unique opportunity to focus, connect and share insights on new formats, payloads, linkers, targets and combinations thereof – and collaborate with fellow innovators in the space!’ - Dantari